Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.68 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7247425 | 0.91 | MAPK14 (0.56) | MAPK14 | |
| SCHEMBL4045888 | 0.76 | KDR (0.65) | MAPK14KDR | |
| SCHEMBL1461091 | 0.74 | KDR (0.65) | MAPK14KDR | |
| SCHEMBL13755665 | 0.72 | MAPK14 (0.87) | MAPK14 | |
| SCHEMBL4108826 | 0.72 | MAPK14 (0.85) | MAPK14 | |
| SCHEMBL5511762 | 0.71 | KDR (0.79) | MAPK14KDR | |
| SCHEMBL1226861 | 0.71 | KDR (1.00) | MAPK14KDR | |
| SCHEMBL12729599 | 0.71 | MAPK14 (0.80) | MAPK14 | |
| SCHEMBL4048119 | 0.70 | KDR (0.52) | MAPK14KDR | |
| SCHEMBL16576239 | 0.70 | MAPK14 (1.00) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227567-A1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227567-A1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP3K5, MAPK1, MAPKAPK5 | MAPK14 29/4885KDR 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.